SCHEMBL20880100

SCHEMBL20880100

O=C1CCCC(O)N1CCc1nc2ccccc2s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 2/20 0.53
HCRTR2 O43614 2/20 0.53
ALOX15 P16050 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
DRD2 P14416 7/20 0.44
HTR1A P08908 6/20 0.44
HTR7 P34969 5/20 0.44
SLC6A4 P31645 3/20 0.44
POLB P06746 2/20 0.43
RECQL P46063 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
HPGD P15428 2/20 0.43
RAB9A P51151 1/20 0.43
DRD3 P35462 6/20 0.43
DRD4 P21917 4/20 0.43
HTR2C P28335 4/20 0.42
HRH1 P35367 4/20 0.42
HTR2B P41595 3/20 0.42
HTR2A P28223 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17525605 0.79 HTR1A (0.50) HCRTR1HCRTR2ALOX15HTTSMN1; SMN2
SCHEMBL20880130 0.79 HTR1A (0.50) HCRTR1HCRTR2ALOX15HTTSMN1; SMN2
SCHEMBL22538918 0.72 FDPS (0.35) HCRTR1HCRTR2ALDH1A1MAPT
SCHEMBL24691383 0.70 DRD2 (0.59) DRD2HTR1AHTR7SLC6A4DRD3
SCHEMBL17500049 0.70 HTR1A (0.47) ALOX15HTTSMN1; SMN2DRD2HTR1A
SCHEMBL15238464 0.69 HCRTR2 (1.00) HCRTR1HCRTR2
SCHEMBL3919004 0.69 UBE2T (0.61) ALOX15HTTSMN1; SMN2L3MBTL1HPGD
SCHEMBL19372016 0.68 UBE2T (0.70) ALOX15HTTSMN1; SMN2DRD2HTR1A
SCHEMBL22144448 0.68 HCRTR1 (0.44) HCRTR1HCRTR2ALOX15HTTSMN1; SMN2
SCHEMBL22538944 0.68 HRH3 (0.52) HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3466425-A1 PHARMACEUTICAL COMPOSITION COMPRISING GLUTARIMIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF EOSINOPHILIC DISEASES Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" (RU) 2019-04-10 EP disclosed